{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:08:20Z","timestamp":1793048900950,"version":"4.5.0"},"reference-count":52,"publisher":"American Association for Cancer Research (AACR)","issue":"18","funder":[{"DOI":"10.13039\/100000002","name":"NIH NCI","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA16672"],"award-info":[{"award-number":["P30 CA16672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>High-risk human papillomavirus (HPV)\u2013associated squamous cell carcinomas of the oropharynx (SCCOP) are among the fastest growing cancers. After standard-of-care treatment, however, patients with HPV+ SCCOP have better overall and disease-specific survival than patients with HPV\u2212 SCCOP, suggesting the importance of HPV-specific immunity. We reasoned that therapeutic vaccination targeting the HPV-16 E6 and E7 oncogenes could elicit high-affinity, high-frequency tumor antigen\u2013specific T-cell responses, which could then be augmented and shielded from suppression in the tumor microenvironment by immune checkpoint modulation. In this study, we used a preclinical syngeneic mouse model of oral cancer comprised of mouse tonsil-derived epithelial cells stably expressing HPV-16 E6 and E7 genes along with H-ras oncogene (mEER) to identify combinations of vaccination and checkpoint antibodies capable of promoting tumor regression. Intranasal HPV E6\/E7 peptide vaccination and single checkpoint antibodies failed to elicit responses in more than half of animals; however, 4-1BB agonist antibody along with either CD40 agonist antibody or CTLA-4 blockade eliminated the majority of established mEER tumors. The combination of intranasal HPV peptide vaccine and \u03b14-1BB and \u03b1CTLA-4 antibodies produced curative efficacy and a better safety profile against orally implanted mEER tumors. Correlates of protective immunity included enhanced intratumoral levels of CD8 T cells relative to immunosuppressive regulatory T cells and myeloid-derived suppressor cells. Overall, our results demonstrate combination vaccine-immunotherapy modalities as novel treatment options for HPV+ SCCOP.<\/jats:p>\n                  <jats:p>Significance: Combinations of vaccine and checkpoint modulation are effective and safe treatment options for HPV+ oral cancers. Cancer Res; 78(18); 5327\u201339. \u00a92018 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-18-0892","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T10:25:20Z","timestamp":1532687120000},"page":"5327-5339","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Mucosal HPV E6\/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers"],"prefix":"10.1158","volume":"78","author":[{"given":"Stephanie","family":"Dorta-Estremera","sequence":"first","affiliation":[{"name":"1Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee L.","family":"Chin","sequence":"additional","affiliation":[{"name":"1Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8398-7477","authenticated-orcid":false,"given":"Gloria","family":"Sierra","sequence":"additional","affiliation":[{"name":"1Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at Houston, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Nicholas","sequence":"additional","affiliation":[{"name":"1Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananta V.","family":"Yanamandra","sequence":"additional","affiliation":[{"name":"1Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sita M.K.","family":"Nookala","sequence":"additional","affiliation":[{"name":"1Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Yang","sequence":"additional","affiliation":[{"name":"3The University of Texas MD Anderson Cancer Center, Oncology Research for Biologics and Immunotherapy Translation, Houston, Texas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shail","family":"Singh","sequence":"additional","affiliation":[{"name":"4Department of Melanoma and Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Curran","sequence":"additional","affiliation":[{"name":"1Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at Houston, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Jagannadha","family":"Sastry","sequence":"additional","affiliation":[{"name":"1Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at Houston, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2018,9,14]]},"reference":[{"key":"2022061706195282300_bib1","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022061706195282300_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/cancers8040041","article-title":"HPV positive head and neck cancers: molecular pathogenesis and evolving treatment strategies","volume":"8","author":"Dok","year":"2016","journal-title":"Cancers"},{"key":"2022061706195282300_bib3","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/ijc.28112","article-title":"Head and neck cancer: from anatomy to biology","volume":"133","author":"Bose","year":"2013","journal-title":"Int J Cancer"},{"key":"2022061706195282300_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2016.01.002","article-title":"Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment","author":"Arina","year":"2016","journal-title":"Semin Immunol"},{"key":"2022061706195282300_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2249.2009.03912.x","article-title":"Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists","volume":"157","author":"Peggs","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"2022061706195282300_bib6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061706195282300_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12180","article-title":"Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma","volume":"1291","author":"Wolchok","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"2022061706195282300_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-092012-112807","article-title":"Immune modulation in cancer with antibodies","volume":"65","author":"Page","year":"2014","journal-title":"Annu Rev Med"},{"key":"2022061706195282300_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cytogfr.2013.12.003","article-title":"Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection","volume":"25","author":"Clouthier","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"2022061706195282300_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2015.08.021","article-title":"Rationale for anti-OX40 cancer immunotherapy","volume":"52","author":"Aspeslagh","year":"2016","journal-title":"Eur J Cancer"},{"key":"2022061706195282300_bib11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1084\/jem.20121190","article-title":"Systemic 4\u20131BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin","volume":"210","author":"Curran","year":"2013","journal-title":"J Exp Med"},{"key":"2022061706195282300_bib12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/08923973.2014.890626","article-title":"Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials","volume":"36","author":"Hassan","year":"2014","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2022061706195282300_bib13","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00262-014-1650-8","article-title":"Immune checkpoint combinations from mouse to man","volume":"64","author":"Ai","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"2022061706195282300_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"2022061706195282300_bib15","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1080\/14760584.2016.1176533","article-title":"Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies","volume":"15","author":"Vici","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2022061706195282300_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12929-016-0293-9","article-title":"Perspectives for therapeutic HPV vaccine development","volume":"23","author":"Yang","year":"2016","journal-title":"J Biomed Sci"},{"key":"2022061706195282300_bib17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/archotol.133.5.495","article-title":"The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium","volume":"133","author":"Hoover","year":"2007","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2022061706195282300_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/bjc.1995.287","article-title":"Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck","volume":"72","author":"Kiaris","year":"1995","journal-title":"Br J Cancer"},{"key":"2022061706195282300_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1158\/0008-5472.CAN-03-2144","article-title":"Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck","volume":"64","author":"Ginos","year":"2004","journal-title":"Cancer Res"},{"key":"2022061706195282300_bib20","doi-asserted-by":"crossref","first-page":"E5290","DOI":"10.1073\/pnas.1514418112","article-title":"Unique potential of 4\u20131BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6\/E7 peptide vaccine","volume":"112","author":"Bartkowiak","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706195282300_bib21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/hed.21040","article-title":"Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC","volume":"31","author":"Williams","year":"2009","journal-title":"Head Neck"},{"key":"2022061706195282300_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1480-9222-16-4","article-title":"Isolation of T cells from mouse oral tissues","volume":"16","author":"Pandiyan","year":"2014","journal-title":"Biol Proced Online"},{"key":"2022061706195282300_bib23","doi-asserted-by":"crossref","first-page":"172ra120","DOI":"10.1126\/scitranslmed.3004888","article-title":"Mucosal imprinting of vaccine-induced CD8(+) T cells is crucial to inhibit the growth of mucosal tumors","volume":"5","author":"Sandoval","year":"2013","journal-title":"Sci Translat Med"},{"key":"2022061706195282300_bib24","first-page":"765","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","author":"Dyck","year":"2017"},{"key":"2022061706195282300_bib25","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706195282300_bib26","doi-asserted-by":"crossref","first-page":"e19499","DOI":"10.1371\/journal.pone.0019499","article-title":"Combination CTLA-4 blockade and 4\u20131BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production","volume":"6","author":"Curran","year":"2011","journal-title":"PLoS ONE"},{"key":"2022061706195282300_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1084\/jem.20030324","article-title":"Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein","volume":"198","author":"Fujii","year":"2003","journal-title":"J Exp Med"},{"key":"2022061706195282300_bib28","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/eji.201041359","article-title":"Intranasal but not intravenous delivery of the adjuvant alpha-galactosylceramide permits repeated stimulation of natural killer T cells in the lung","volume":"41","author":"Courtney","year":"2011","journal-title":"Eur J Immunol"},{"key":"2022061706195282300_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"2022061706195282300_bib30","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti\u2013CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"2022061706195282300_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/iid3.144","article-title":"Location of tumor affects local and distant immune cell type and number","volume":"5","author":"Hensel","year":"2017","journal-title":"Immun Inflamm Dis"},{"key":"2022061706195282300_bib32","doi-asserted-by":"crossref","first-page":"54775","DOI":"10.18632\/oncotarget.18423","article-title":"Tumor location impacts immune response in mouse models of colon cancer","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"2022061706195282300_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3322\/caac.21293","article-title":"Oral cavity and oropharyngeal squamous cell carcinoma\u2013an update","volume":"65","author":"Chi","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2022061706195282300_bib34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1172\/JCI23373","article-title":"Rapid and strong human CD8(+) T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909","volume":"115","author":"Speiser","year":"2005","journal-title":"J Clin Investigat"},{"key":"2022061706195282300_bib35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clim.2010.11.010","article-title":"Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B\/C infection","volume":"140","author":"Schneiders","year":"2011","journal-title":"Clin Immunol"},{"key":"2022061706195282300_bib36","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-17-1847","article-title":"Activation of 4\u20131BB on liver myeloid cells triggers hepatitis via an interleukin-27-dependent pathway","volume":"24","author":"Bartkowiak","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2022061706195282300_bib37","doi-asserted-by":"crossref","first-page":"17352","DOI":"10.3748\/wjg.v20.i46.17352","article-title":"Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management","volume":"20","author":"Rossi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2022061706195282300_bib38","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2022061706195282300_bib39","doi-asserted-by":"crossref","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","article-title":"PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy?","volume":"7","author":"Simon","year":"2018","journal-title":"Oncoimmunology"},{"key":"2022061706195282300_bib40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ijos.2014.48","article-title":"The mucosal immune system in the oral cavity\u2014an orchestra of T cell diversity","volume":"6","author":"Wu","year":"2014","journal-title":"Int J Oral Sci"},{"key":"2022061706195282300_bib41","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3389\/fimmu.2017.00250","article-title":"Phenotype and tissue residency of lymphocytes in the murine oral mucosa","volume":"8","author":"Park","year":"2017","journal-title":"Front Immunol"},{"key":"2022061706195282300_bib42","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2217\/imt.11.62","article-title":"Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients","volume":"3","author":"Hardwick","year":"2011","journal-title":"Immunotherapy"},{"key":"2022061706195282300_bib43","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"The Cancer Genome Atlas, N","year":"2015","journal-title":"Nature"},{"key":"2022061706195282300_bib44","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2008.21.3017","article-title":"Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma","volume":"27","author":"Advani","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022061706195282300_bib45","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4161\/cbt.10.10.13251","article-title":"Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors","volume":"10","author":"Ruter","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"2022061706195282300_bib46","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science (New York, N.y.)"},{"key":"2022061706195282300_bib47","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/eji.201445093","article-title":"CD40 dependent exacerbation of immune mediated hepatitis by hepatic CD11b(+) Gr-1(+) myeloid derived suppressor cells in tumor bearing mice","volume":"45","author":"Kapanadze","year":"2015","journal-title":"Eur J Immunol"},{"key":"2022061706195282300_bib48","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.4049\/jimmunol.1201854","article-title":"GITR-dependent regulation of 4\u20131BB expression: implications for T cell memory and anti-4\u20131BB-induced pathology","volume":"190","author":"Lin","year":"2013","journal-title":"J Immunol"},{"key":"2022061706195282300_bib49","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1158\/1078-0432.CCR-10-0385","article-title":"AdCD40L immunogene therapy for bladder carcinoma\u2014the first phase I\/IIa trial","volume":"16","author":"Malmstrom","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022061706195282300_bib50","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/bjc.2016.42","article-title":"Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients","volume":"114","author":"Loskog","year":"2016","journal-title":"Br J Cancer"},{"key":"2022061706195282300_bib51","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.vaccine.2015.06.087","article-title":"An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4\u20131BBL leads to delayed tumor progression","volume":"34","author":"Ragonnaud","year":"2016","journal-title":"Vaccine"},{"key":"2022061706195282300_bib52","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.1158\/0008-5472.CAN-05-2128","article-title":"Combination therapy with anti-CTL antigen-4 and anti-4\u20131BB antibodies enhances cancer immunity and reduces autoimmunity","volume":"66","author":"Kocak","year":"2006","journal-title":"Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/18\/5327\/2770239\/5327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/18\/5327\/2770239\/5327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T14:28:39Z","timestamp":1655476119000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/78\/18\/5327\/631718\/Mucosal-HPV-E6-E7-Peptide-Vaccination-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,14]]},"references-count":52,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2018,9,14]]},"published-print":{"date-parts":[[2018,9,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-18-0892","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22420130","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420142","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420142.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420127","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420139","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420136.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420136","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6510566","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6510566.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420124","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420139.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420121","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420133","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420133.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420130.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420121.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420124.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420127.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,14]]}}}